rates with boceprevir (Victrelis, Merck & Co.) and telaprevir
(Incivek, Vertex Pharmaceuticals) are much higher in the real-world
setting than in the clinical trials that led to the drugs’ approvals.
This news comes from two studies presented at The Liver Meeting, the
annual meeting of the American Association for the Study of Liver
Researchers say that treatment rates are low because of the
complexity of treatment with the direct-acting antivirals (DAA) and
concerns about side effects, even at experienced centers. The FDA
approved boceprevir and telaprevir for the treatment of patients with
hepatitis C virus (HCV) genotype 1 infection in combination with
pegylated interferon and ribavirin in 2011.